Jasmine A. Luzum
Pharmacology, Toxicology and Pharmaceutics · University of Michigan
Publications
80
Citations
2,021
Est. group size
~6
Recurring co-author estimate
Active years
13
Publishing since 2014
Typically publishes in teams of ~8 · 17% small-team papers (≤3 authors) · across 24 venues
- 2025 Acute Coronary Syndrome Guideline: Missing the Boat on <i>CYP2C19</i> Genotyping
Journal of the American Heart Association · 2026
- Direct-to-Consumer Genetic Testing for Cardiovascular Disease: A Scientific Statement From the American Heart Association
Circulation · 2025
- Association of Plasma Metabolites and Cardiac Mitochondrial Function with Heart Failure Progression
ESC Heart Failure · 2025
- Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion
Pharmacogenomics · 2025
- <i>CYP2C19</i> Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association
Circulation · 2024
- Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for <i>CYP2D6</i>, <i>ADRB1</i>, <i>ADRB2</i>, <i>ADRA2C</i>, <i>GRK4</i>, and <i>GRK5</i> Genotypes and Beta‐Blocker Therapy
Clinical Pharmacology & Therapeutics · 2024
- Genetic drivers of human plasma metabolites that determine mortality in heart failure patients with reduced ejection fraction
Frontiers in Cardiovascular Medicine · 2024
- Equal Treatment, Unequal Outcomes? Debunking the Racial Disparity in Renin Angiotensin Aldosterone System Inhibitor–Associated Reduction in Heart Failure Hospitalizations
Journal of Cardiac Failure · 2024
- It is time for educators to act: pharmacogenomics education and its implementation into clinical practice
Pharmacogenomics · 2024
- Pharmacogenetic Considerations in Beta-Blocker Therapy
SMART-MD journal of precision medicine. · 2024
- Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank
Circulation Genomic and Precision Medicine · 2023
- An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
Clinical Pharmacology & Therapeutics · 2023
- Common Variants on <i>FGD5</i> Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial
Circulation Heart Failure · 2023
- Evaluation of a New Aptamer-Based Array for Soluble Suppressor of Tumorgenicity (ST2) and N-terminal Pro-B-Type Natriuretic Peptide (NTproBNP) in Heart Failure Patients
Journal of Cardiovascular Translational Research · 2023
- ASSOCIATION OF PLASMA METABOLITES AND CARDIAC MITOCHONDRIAL FUNCTION WITH HEART FAILURE PROGRESSION
Journal of the American College of Cardiology · 2023
- Pharmacogenomics×8
- Circulation×6
- Journal of the American College of Cardiology×6
- Clinical Pharmacology & Therapeutics×5
- Journal of Cardiac Failure×5
- Tyler Shugg
Pharmacology, Toxicology and Pharmaceutics · Indiana University
- Aditi Shendre
Pharmacology, Toxicology and Pharmaceutics · The Ohio State University
- Emily E. Scott
Pharmacology, Toxicology and Pharmaceutics · University of Michigan
- Amy L. Pasternak
Pharmacology, Toxicology and Pharmaceutics · University of Michigan
- Hao Chen
Pharmacology, Toxicology and Pharmaceutics · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile